We're not getting any younger... yet.

The Buck Institute
  • ٠٫٠ (٠)
  • علوم حياة
  • يتم التحديث أسبوعيًا

Why do some of us age gracefully and others don’t? How do our bodies and minds experience aging at the cellular and molecular level? Why do we even age to begin with? And maybe most importantly, can we do anything about it? Join hosts Eric Verdin, CEO of the Buck Institute in California, and Brianna Stubbs, Director of Translational Science at the Buck, as they speak with some of the brightest scientific stars on the planet to search for – and actually find answers to – these questions and many more.

  1. Tony Wyss-Coray: Rejuvenating the Brain

    ٤ فبراير

    Tony Wyss-Coray: Rejuvenating the Brain

    In this episode, Eric Verdin, CEO of the Buck Institute, and Stanford University’s Dr. Tony Wyss-Coray discuss the groundbreaking science of brain rejuvenation through heterochronic parabiosis, a process where young blood factors are shown to restore cognitive function and potentially extend lifespan. Moving from the lab to the clinic, they explore the next frontier: Proteomic Clocks. By measuring thousands of proteins, scientists can now determine the biological age of individual organs, allowing for the detection of Alzheimer’s and other neurodegenerative diseases up to 15 years before symptoms appear. This shift toward high-precision organ tracking marks a new era in preventative geroscience and personalized longevity. Tony Wyss-Coray is a Professor of Neurology and Neurological Sciences and the Director of the Phil and Penny Knight Initiative for Brain Resilience at Stanford University. His lab studies brain aging and neurodegeneration with a focus on age-related cognitive decline and Alzheimer’s disease. The Wyss-Coray research team discovered that circulatory blood factors can modulate brain structure and function and factors from young organisms can rejuvenate old brains. Current studies focus on the molecular basis of the systemic communication with the brain by employing a combination of genetic, cell biology, and –omics approaches in killifish, mice, and humans. Wyss-Coray has presented his ideas at Global TED, the Tencent WE Summit, and the World Economic Forum. He co-founded Alkahest Inc. and several other companies targeting Alzheimer’s and neurodegeneration and has been the recipient of an NIH Director’s Pioneer Award, a Zenith Award from the Alzheimer’s Association, and a NOMIS Foundation Award. Support the show

    ٤٦ من الدقائق
  2. George Church: Rewriting The Rules of Aging

    ٢١ يناير

    George Church: Rewriting The Rules of Aging

    What if aging is less a fate and more an engineering challenge? We sit down with George Church to unpack a future where gene therapy, cellular reprogramming, and AI-driven delivery systems converge to extend healthspan—and possibly lifespan—without sacrificing identity or safety. From bowhead whales and cancer risk to ethics, trial rigor, and how to deliver rejuvenation to the brain, this is a deep dive into what’s coming next and what it will take to get there. George Church is Professor of Genetics at Harvard Medical School and Professor of Health Sciences and Technology at Harvard and the Massachusetts Institute of Technology (MIT). He is Director of the U.S. Department of Energy Technology Center and Director of the National Institutes of Health Center of Excellence in Genomic Science. He has received numerous awards including the 2011 Bower Award and Prize for Achievement in Science from the Franklin Institute and election to the National Academy of Sciences and Engineering. Support the show

    ٤٠ من الدقائق

  3. المقطع الترويجي للموسم ٣

    Season 3 Trailer

    We're back! Meet our new hosts Eric Verdin, CEO of the Buck Institute, and Brianna Stubbs, Director of Translational Science at the Buck. We're excited to bring you new insights into the fast-moving science of longevity with guests such as George Church, Jamie Justice, Peter Attia, and many more. Support the show

    ١ من الدقائق

  4. ٢٤‏/٠٧‏/٢٠٢٤

    Nathan Price: Scientific Wellness and AI at the Forefront

    What do we really want from our healthcare system, and how can AI help us get it sooner? In our final episode of season two, Gordon talks with visionary systems biology expert Nathan Price about the emergence of scientific wellness, what we can learn from our digital twins, and how using AI to predict health outcomes can help us transform our understanding of aging and disease—potentially adding years of healthy life. Dr. Nathan Price is a distinguished scientist and leader in the field of healthy aging, holding dual roles as Professor and Co-Director of the Center for Human Healthspan at the Buck Institute for Research on Aging and Chief Scientific Officer at Thorne. He co-authored the bestselling book The Age of Scientific Wellness with Dr. Lee Hood, and has an extensive publication record, including over 200 scientific papers and contributions to prominent media outlets. Recognized as one of the National Academy of Medicine's Emerging Leaders in Health and Medicine in 2019, Dr. Price also serves on the Board on Life Sciences of the National Academies of Sciences, Engineering, and Medicine. His career includes significant positions such as CEO of Onegevity, a health AI company, and a decade-long tenure at the Institute for Systems Biology. Dr. Price's contributions to science and business have earned him numerous awards, including an NSF CAREER award and the Grace A. Goldsmith Award. He has also been elected a fellow of the American Institute for Medical and Biological Engineering and recognized as a Notable Leader in Healthcare by Crain's New York. His advisory roles span prestigious organizations like Roche, Providence St Joseph Health, and the American Cancer Society. Support the show

    ٣٣ من الدقائق

  5. ١٠‏/٠٧‏/٢٠٢٤

    Luigi Ferrucci: Resilience as Medicine

    Few people have as much experience with patient care and long-term research as the celebrated geriatrician and epidemiologist Luigi Ferrucci. Listen in as he speaks with Gordon about his journey from acute care to population studies, the effective design of clinical trials, and moving towards predictive medicine so we can use our natural resilience to maintain health as we age. Dr. Luigi Ferrucci is a geriatrician and an epidemiologist who conducts research on the causal pathways leading to progressive physical and cognitive decline in older persons. In September 2002, he became the Chief of the Longitudinal Studies Section at NIA and the Director of the Baltimore Longitudinal Study on Aging. Dr. Ferrucci received a Medical Degree and Board Certification in 1980, a Board Certification in Geriatrics in 1982 and Ph.D. in Biology and Pathophysiology of Aging in 1998 at the University of Florence, Italy. Between 1985 and 2002 he was Chief of Geriatric Rehabilitation at the Department of Geriatric Medicine and Director of the Laboratory of Clinical Epidemiology at the Italian National Institute of Aging. During the same period, he collaborated with the NIA Laboratory of Epidemiology, Demography, and Biometry where he spent several periods as Visiting Scientist at NIH. Dr. Ferrucci has made major contributions in the design of many epidemiological studies conducted in the U.S. and in Europe, including the AKEA study of Centenarians in Sardinia and the Women's Health and Aging Study. He was also the Principal Investigator of the InCHIANTI study, a longitudinal study conducted in the Chianti Geographical area (Tuscany, Italy) looking at risk factors for mobility disability in older persons. In 2002, Dr. Ferrucci refined the design of the Baltimore Longitudinal Study of Aging to focus on the Geroscience Hypothesis, which states the pace of biological aging is the root cause of many age-related chronic diseases, as well as physical and cognitive disability. He has made major contributions to the literature and is one of the most cited scientists in the field of aging. Dr. Ferrucci has been Scientific Director at NIA since May 2011. Support the show

    ٤٦ من الدقائق

  6. ١٢‏/٠٦‏/٢٠٢٤

    Andrea Maier: From Potential to Practice

    The movement to integrate longevity treatments into clinical care is making strides. How can we ensure they are evidence-based, accessible, and personalized? World-renowned geroscientist Andrea Maier has been leading the way with innovative clinical trials and cutting edge research. In this episode, she talks with Gordon about the current state of the field, why we need a variety of clocks and interventions, what we can all do now to age better, and what the future of clinical practice looks like. Professor Andrea Maier is a prolific researcher in the field of geroscience — the intersection of aging biology, chronic disease, and health. A principal investigator in gerontology, as well as a specialist in internal medicine and geriatrics, Professor Maier's aging research focuses on age-related diseases, cellular senescence and the translation of results into clinical practice. She has published almost 400 peer-reviewed articles and has spearheaded significant contributions of her highly acclaimed innovative, global, multidisciplinary work with her @Age Research Group. Professor Maier holds professorship appointments at VU University Medical Centre, Amsterdam, Netherlands and University of Melbourne, Australia. Professor Maier is the past President of the Australia and New Zealand Society for Sarcopenia and Frailty Research and founding president of the Healthy Longevity Medicine Society. She sits on several prestigious international academic and health policy committees and organizations, including national and international research funding agencies and the World Health Organization. Support the show

    ٣٦ من الدقائق

  7. ٢٩‏/٠٥‏/٢٠٢٤

    Daniel Belsky: Measuring the Pace of Aging

    Our chronological age doesn’t tell us much about how well our bodies are aging, but scientists have developed many ways to measure changes at the cellular and molecular levels, including the rate of change, that can suggest ways to improve health at every stage of life. Follow along as Gordon speaks with Daniel Belsky of Columbia University about DNA methylation, the effects of famine and poverty on aging biology, studying the exposome, and how to create equitable access to potential aging interventions. Dr. Belsky is an Associate Professor of Epidemiology in the Robert N. Butler Columbia Aging Center at Columbia University. His studies seek to understand how genes and environments combine to shape health across the life course. The goal of Dan's work is to reduce social inequalities in aging outcomes in the US and elsewhere. With collaborators Terrie Moffitt and Avshalom Caspi he originated the Pace of Aging method to quantify the aging process from longitudinal analysis of human physiology and recently translated this method into a DNA-methylation blood test that can be implemented from a single time point of data collection. He is principal investigator of NIH-funded projects to test how caloric restriction may slow or reverse aging-related changes to the genome (CALERIE), to understand long-term impacts of in-utero famine exposure on biological aging (Dutch Hunger Winter Family Study, with Bertie Lumey), and to test the potential of anti-poverty policy intervention to slow biological aging (MyGoals for Healthy Aging, with Peter Muennig). Dan's work has received international attention, including by the Wall Street Journal, Washington Post, and Guardian newspapers, and appeared in outlets including PNAS, Nature Human Behaviour, Nature Aging, the JAMA journals, Lancet Respiratory Medicine, and top journals in epidemiology and gerontology. Since 2020, he has been named an ISI highly-cited researcher. Support the show

    ٣٩ من الدقائق

  8. ١٥‏/٠٥‏/٢٠٢٤

    Kristen Fortney: Finding Targets for Aging Interventions

    Of all the biochemical changes that occur with aging, what really matters? How can we use the incredible amount of health data available today to discover the best targets for interventions? In this episode, Kristen Fortney of BioAge talks with Gordon about the latest research in proteomics and metabolomics, the importance of muscle loss, and the challenge of measuring the right endpoints for effective treatment and regulatory approval. Kristen Fortney is the co-founder and CEO of BioAge, a clinical-stage biotechnology company developing a pipeline of treatments to extend healthy lifespan by targeting the molecular causes of aging. The company uses its discovery platform, which combines quantitative analysis of proprietary longitudinal human samples with detailed health records tracking individuals over the lifespan, to map out the key molecular pathways that impact healthy human longevity. By targeting these pathways with a large and mechanistically diverse portfolio of drugs, BioAge is unlocking opportunities to treat and prevent diseases of aging in entirely new ways. Kristen’s scientific background is in aging biology and bioinformatics. She received her PhD in Medical Biophysics from the University of Toronto, followed by postdoctoral training at Stanford University, where she was a fellow of the Ellison Medical Foundation & American Federation for Aging Research. Support the show

    ٢٧ من الدقائق
مشاهدة الكل (٢٩)

مقاطع ترويجية

حول

Why do some of us age gracefully and others don’t? How do our bodies and minds experience aging at the cellular and molecular level? Why do we even age to begin with? And maybe most importantly, can we do anything about it? Join hosts Eric Verdin, CEO of the Buck Institute in California, and Brianna Stubbs, Director of Translational Science at the Buck, as they speak with some of the brightest scientific stars on the planet to search for – and actually find answers to – these questions and many more.

المعلومات

  • صناع العمل
    The Buck Institute
  • سنوات النشاط
    ٢٠٢٢ - ٢٠٢٦
  • الحلقات
    ٢٩
  • التقييم
    فاضح
  • حقوق النشر
    © 2026 Buck Institute for Research on Aging
  • موقع البرنامج على الويب
    We're not getting any younger... yet.

قد يعجبك أيضًا